Cdk2 plays a critical role in hepatocyte cell cycle progression and survival in the setting of cyclin D1 expression in vivo

Cell Cycle

Volumn 8, Issue 17, 2009, Pages 2802-2809

  Hanse, Eric A ^a,b   Nelsen, Christopher J ^b   Goggin, Melissa M ^b   Anttila, Chelsea K ^b   Mullany, Lisa K ^b   Berthet, Cyril ^c   Kaldis, Philipp ^c   Crary, Gretchen S ^a   Kuriyama, Ryoko ^d   Albrecht, Jeffrey H ^a,b  

^a HENNEPIN COUNTY MEDICAL CENTER   (United States)

^b MINNEAPOLIS MEDICAL RESEARCH FOUNDATION   (United States)

^c NATIONAL CANCER INSTITUTE   (United States)

^d UNIVERSITY OF MINNESOTA   (United States)

Author keywords

Apoptosis; cdk2; Centrosomes; Cyclin D1; Liver regeneration; Seliciclib

Indexed keywords

CYCLIN D1; CYCLIN DEPENDENT KINASE 2; ROSCOVITINE;

ANIMAL CELL; ANIMAL EXPERIMENT; ARTICLE; CELL CYCLE PROGRESSION; CELL PROLIFERATION; CELL SURVIVAL; CENTROSOME; DEATH; LIVER CELL; LIVER CELL DAMAGE; MITOSIS; MOUSE; NONHUMAN; PARTIAL HEPATECTOMY; PROTEIN EXPRESSION; TRANSIENT EXPRESSION;

ANIMALIA; MUS;

EID: 69749119833     PISSN: 15384101     EISSN: 15514005     Source Type: Journal    
DOI: 10.4161/cc.8.17.9465     Document Type: Article

References (49)

1. Fausto N, Campbell JS, Riehle KJ. Liver regeneration. Hepatology 2006; 43:45-53.
2. Michalopoulos GK. Liver regeneration. J Cell Physiol 2007; 213:286-300.
3. Grisham JW. Molecular Biology of Hepatocellular Carcinoma. In: Abbruzzese JL, Evans DB, Willett CG, Fenoglio-Preiser C, eds. Gastrointestinal Oncology. New York: Oxford University Press 2004; 471-506.
4. El-Serag HB, Rudolph KL. Hepatocellular carcinoma: epidemiology and molecular carcinogenesis. Gastroenterology 2007; 132:2557-2576 (Pubitemid 46890874)
5. Malumbres M, Barbacid M. Cell cycle kinases in cancer. Current Opinion in Genetics & Development 2007; 17:60.
6. Berthet C, Kaldis P. Cell-specific responses to loss of cyclin-dependent kinases. Oncogene 2007. (Pubitemid 47037044)
7. Santamaria D, Ortega S. Cyclins and CDKS in development and cancer: lessons from genetically modified mice. Front Biosci 2006; 11:1164-1188 (Pubitemid 43253468)
8. Albrecht JH, Hansen LK. Cyclin D1 promotes mitogen-independent cell cycle progression in hepatocytes. Cell Growth Differ 1999; 10:397-404.
9. Nelsen CJ, Rickheim DG, Timchenko NA, Stanley MW, Albrecht JH. Transient expression of cyclin D1 is sufficient to promote hepatocyte replication and liver growth in vivo. Cancer Res 2001; 61:8564-8568
10. Coqueret O. Linking cyclins to transcriptional control. Gene 2002; 299:35-55.
11. Fu M, Wang C, Li Z, Sakamaki T, Pestell RG. Minireview: Cyclin D1: normal and abnormal functions. Endocrinology 2004; 145:5439-5447 (Pubitemid 39564581)
12. Nelsen CJ, Kuriyama R, Hirsch B, Negron VC, Lingle WL, Goggin MM, et al. Short term cyclin D1 overexpression induces centrosome amplification, mitotic spindle abnormalities and aneuploidy. J Biol Chem 2005; 280:768-776 (Pubitemid 40165045)
13. Mullany LK, White P, Hanse EA, Nelsen CJ, Goggin MM, Mullany JE, et al. Distinct proliferative and transcriptional effects of the D-type cyclins in vivo. Cell Cycle 2008; 7:2215-2224 (Pubitemid 352031524)
14. Berthet C, Aleem E, Coppola V, Tessarollo L, Kaldis P. Cdk2 knockout mice are viable. Curr Biol 2003; 13:1775-1785 (Pubitemid 37274109)
15. Ortega S, Prieto I, Odajima J, Martin A, Dubus P, Sotillo R, et al. Cyclin-dependent kinase 2 is essential for meiosis but not for mitotic cell division in mice. Nat Genet 2003; 35:25-31. (Pubitemid 37048592)
16. 1/S phase transition. Nat Cell Biol 2005; 7:831-836
17. Golsteyn RM. Cdk1 and Cdk2 complexes (cyclin dependent kinases) in apoptosis: a role beyond the cell cycle. Cancer Letters 2005; 217:129.
18. MacCallum DE, Melville J, Frame S, Watt K, Anderson S, Gianella-Borradori A, et al. Seliciclib (CYC202, R-Roscovitine) induces cell death in multiple myeloma cells by inhibition of RNA polymerase II-dependent transcription and downregulation of Mcl-1. Cancer Res 2005; 65:5399-5407 (Pubitemid 40827353)
19. Bach S, Knockaert M, Reinhardt J, Lozach O, Schmitt S, Baratte B, et al. Roscovitine targets, protein kinases and pyridoxal kinase. J Biol Chem 2005; 280:31208-31219 (Pubitemid 41291858)
20. Shapiro GI. Cyclin-Dependent Kinase Pathways As Targets for Cancer Treatment. J Clin Oncol 2006; 24:1770-1783 (Pubitemid 46628473)
21. Tetsu O, McCormick F. Proliferation of cancer cells despite CDK2 inhibition. Cancer Cell 2003; 3:233-245 (Pubitemid 37443879)
22. Du J, Widlund HR, Horstmann MA, Ramaswamy S, Ross K, Huber WE, et al. Critical role of CDK2 for melanoma growth linked to its melanocyte-specific transcriptional regulation by MITF. Cancer Cell 2004; 6:565-576 (Pubitemid 40017700)
23. Cai D, Latham VM Jr, Zhang X, Shapiro GI. Combined depletion of cell cycle and transcriptional cyclin-dependent kinase activities induces apoptosis in cancer cells. Cancer Res 2006; 66:9270-9280 (Pubitemid 44521149)
24. Deane NG, Parker MA, Aramandla R, Diehl L, Lee WJ, Washington MK, et al. Hepatocellular carcinoma results from chronic cyclin D1 overexpression in transgenic mice. Cancer Res 2001; 61:5389-5395 (Pubitemid 32694916)
25. Fukasawa K. p53, cyclin-dependent kinase and abnormal amplification of centrosomes. Biochimica et Biophysica Acta (BBA) - Reviews on Cancer 2008; 1786:15.
26. Ohta T, Essner R, Ryu JH, Palazzo RE, Uetake Y, Kuriyama R. Characterization of Cep135, a novel coiled-coil centrosomal protein involved in microtubule organization in mammalian cells. J Cell Biol 2002; 156:87-99. (Pubitemid 34846938)
27. Guidotti JE, Bregerie O, Robert A, Debey P, Brechot C, Desdouets C. Liver cell polyploidization: a pivotal role for binuclear hepatocytes. J Biol Chem 2003; 278:19095-19101 (Pubitemid 36799297)
28. Duensing A, Liu Y, Tseng M, Malumbres M, Barbacid M, Duensing S. Cyclin-dependent kinase 2 is dispensable for normal centrosome duplication but required for oncogene-induced centrosome overduplication. Oncogene 2006; 25:2943-2949 (Pubitemid 43739245)
29. Starkel P, De Saeger C, Sempoux C, Legrand E, Leclercq I, Horsmans Y. Blunted DNA synthesis and delayed S-phase entry following inhibition of Cdk2 activity in the regenerating rat liver. Lab Invest 2005; 85:562-571 (Pubitemid 40523946)
30. Albrecht JH, Poon RY, Ahonen CL, Rieland BM, Deng C, Crary GS. Involvement of p21 and p27 in the regulation of CDK activity and cell cycle progression in the regenerating liver. Oncogene 1998; 16:2141-2150 (Pubitemid 28211689)
31. Martin A, Odajima J, Hunt SL, Dubus P, Ortega S, Malumbres M, Barbacid M. Cdk2 is dispensable for cell cycle inhibition and tumor suppression mediated by p27(Kip1) and p21(Cip1). Cancer Cell 2005; 7:591-598 (Pubitemid 40799251)
32. Berthet C, Rodriguez-Galan MC, Hodge DL, Gooya J, Pascal V, Young HA, et al. Hematopoiesis and thymic apoptosis are not affected by the loss of Cdk2. Mol Cell Biol 2007; 27:5079-5089 (Pubitemid 47068283)
33. Jablonska B, Aguirre A, Vandenbosch R, Belachew S, Berthet C, Kaldis P, Gallo V. Cdk2 is critical for proliferation and self-renewal of neural progenitor cells in the adult subventricular zone. J Cell Biol 2007; 179:1231-1245 (Pubitemid 350277741)
34. Vandenbosch R, Borgs L, Beukelaers P, Foidart A, Nguyen L, Moonen G, et al. CDK2 is dispensable for adult hippocampal neurogenesis. Cell Cycle 2007; 6:3065-3069
35. Satyanarayana A, Berthet C, Lopez-Molina J, Coppola V, Tessarollo L, Kaldis P. Genetic substitution of Cdk1 by Cdk2 leads to embryonic lethality and loss of meiotic function of Cdk2. Development 2008; 135:3389-3400
36. Camins A, Verdaguer E, Folch J, Canudas AM, Pallas M. The role of CDK5/P25 formation/inhibition in neurodegeneration. Drug News Perspect 2006; 19:453-460
37. Bukanov NO, Smith LA, Klinger KW, Ledbetter SR, Ibraghimov-Beskrovnaya O. Long-lasting arrest of murine polycystic kidney disease with CDK inhibitor roscovitine. Nature 2006; 444:949-952 (Pubitemid 46025010)
38. Hiromura K, Pippin JW, Fero ML, Roberts JM, Shankland SJ. Modulation of apoptosis by the cyclin-dependent kinase inhibitor p27(Kip1). J Clin Invest 1999; 103:597-604. (Pubitemid 29122412)
39. Deb-Basu D, Aleem E, Kaldis P, Felsher DW. CDK2 is required by MYC to induce apoptosis. Cell Cycle 2006; 5:1342-1347 (Pubitemid 43894291)
40. Liem DA, Zhao P, Angelis E, Chan SS, Zhang J, Wang G, et al. Cyclin-dependent kinase 2 signaling regulates myocardial ischemia/reperfusion injury. J Mol Cell Cardiol 2008; 45:610-616
41. Lacrima K, Rinaldi A, Vignati S, Martin V, Tibiletti MG, Gaidano G, et al. Cyclin-dependent kinase inhibitor seliciclib shows in vitro activity in diffuse large B-cell lymphomas. Leuk Lymphoma 2007; 48:158-167 (Pubitemid 46978635)
42. Weinstein IB, Joe AK. Mechanisms of disease: Oncogene addiction - a rationale for molecular targeting in cancer therapy. Nat Clin Pract Oncol 2006; 3:448-457 (Pubitemid 44203817)
43. Malhi H, Gores GJ. Cellular and molecular mechanisms of liver injury. Gastroenterology 2008; 134:1641-1654 (Pubitemid 351615416)
44. Dai Y, Hamm TE, Dent P, Grant S. Cyclin D1 overexpression increases the susceptibility of human U266 myeloma cells to CDK inhibitors through a process involving p130-, p107- and E2F-dependent S phase entry. Cell Cycle 2006; 5:437-446
45. Rossi AG, Sawatzky DA, Walker A, Ward C, Sheldrake TA, Riley NA, et al. Cyclin-dependent kinase inhibitors enhance the resolution of inflammation by promoting inflammatory cell apoptosis. Nat Med 2006; 12:1056-1064 (Pubitemid 44353387)
46. Kobayashi S, Lee S-H, Meng XW, Mott JL, Bronk SF, Werneburg NW, et al. Serine 64 Phosphorylation Enhances the Antiapoptotic Function of Mcl-1. J Biol Chem 2007; 282:18407-18417 (Pubitemid 47100259)
47. Huang H, Regan KM, Lou Z, Chen J, Tindall DJ. CDK2-dependent phosphorylation of FOXO1 as an apoptotic response to DNA damage. Science 2006; 314:294-297 (Pubitemid 44571973)
48. Mukhopadhyay P, Ali MA, Nandi A, Carreon P, Choy H, Saha D. The Cyclin-Dependent Kinase 2 Inhibitor Downregulates Interleukin-1{beta}-Mediated Induction of Cyclooxygenase-2 Expression in Human Lung Carcinoma Cells. Cancer Res 2006; 66:1758-1766 (Pubitemid 43259961)
49. Rickheim DG, Nelsen CJ, Fassett JT, Timchenko NA, Hansen LK, Albrecht JH. Differential regulation of cyclins D1 and D3 in hepatocyte proliferation. Hepatology 2002; 36:30-38 (Pubitemid 34700759)